Moderna, Inc. — Director's Dealing 2021

Apr 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-04-19

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-19	Common Stock	M	5000	$12.21	Acquired	5000	Direct
2021-04-19	Common Stock	S	656	$160.48	Disposed	4344	Direct
2021-04-19	Common Stock	S	1332	$161.62	Disposed	3012	Direct
2021-04-19	Common Stock	S	1250	$162.65	Disposed	1762	Direct
2021-04-19	Common Stock	S	500	$163.89	Disposed	1262	Direct
2021-04-19	Common Stock	S	462	$165.04	Disposed	800	Direct
2021-04-19	Common Stock	S	700	$166.31	Disposed	100	Direct
2021-04-19	Common Stock	S	100	$167.56	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-19	Stock Option (Right to Buy)	$12.21	M	5000	Disposed	2027-10-03	Common Stock (5000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.04 to $160.88. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.14 to $162.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.22 to $163.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.50 to $164.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.71 to $165.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.07 to $166.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).